• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Microbiol Spectr . Genomic Characterization of SARS-CoV-2 Isolated from Patients with Distinct Disease Outcomes in Mexico

tetano

Editor, Senior Moderator
Microbiol Spectr


. 2022 Jan 12;e0124921.
doi: 10.1128/spectrum.01249-21. Online ahead of print.
Genomic Characterization of SARS-CoV-2 Isolated from Patients with Distinct Disease Outcomes in Mexico


Celia Boukadida[SUP] #[/SUP][SUP] 1 [/SUP], Blanca Taboada[SUP] #[/SUP][SUP] 2 [/SUP], Marina Escalera-Zamudio[SUP] 3 [/SUP], Pavel Isa[SUP] 2 [/SUP], José Ernesto Ramírez-González[SUP] 4 [/SUP], Joel Armando Vazquez-Perez[SUP] 5 [/SUP], José Esteban Muñoz-Medina[SUP] 6 [/SUP], Concepción Grajales-Muñiz[SUP] 7 [/SUP], Carolina González-Torres[SUP] 8 [/SUP], Francisco Javier Gaytán-Cervantes[SUP] 8 [/SUP], Alma Rincón-Rubio[SUP] 1 [/SUP], Margarita Matías-Florentino[SUP] 1 [/SUP], Héctor Esteban Paz-Juárez[SUP] 1 [/SUP], Alejandro Sanchez-Flores[SUP] 9 [/SUP], Edgar Mendieta-Condado[SUP] 4 [/SUP], Gisela Barrera-Badillo[SUP] 4 [/SUP], Lucía Hernández-Rivas[SUP] 4 [/SUP], Susana López[SUP] 2 [/SUP], Irma López-Martínez[SUP] 4 [/SUP], Santiago Ávila-Ríos[SUP] 1 [/SUP], Carlos F Arias[SUP] 2 [/SUP]



Affiliations

Abstract

The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has shown a wide spectrum of clinical manifestations ranging from asymptomatic infections to severe disease and death. Pre-existing medical conditions and age have been mainly linked to the development of severe disease; however, the potential association of viral genetic characteristics with different clinical conditions remains unclear. SARS-CoV-2 variants with increased transmissibility were detected early in the pandemics, and several variants with potential relevance for public health are currently circulating around the world. In this study, we characterized 57 complete SARS-CoV-2 genomes during the exponential growth phase of the early epidemiological curve in Mexico, in April 2020. Patients were categorized under distinct disease severity outcomes: mild disease or ambulatory care, severe disease or hospitalized, and deceased. To reduce bias related to risk factors, the patients were less than 60 years old and with no diagnosed comorbidities A trait-association phylogenomic approach was used to explore genotype-phenotype associations, represented by the co-occurrence of mutations, disease severity outcome categories, and clusters of Mexican sequences. Phylogenetic results revealed a higher genomic diversity compared to the initial viruses detected during the early stage of the local epidemic. We identified a total of 90 single nucleotide variants compared to the Wuhan-Hu-1 genome, including 54 nonsynonymous mutations. We did not find evidence for the co-occurrence of mutations associated with specific disease outcomes. Therefore, in the group of patients studied, disease severity was likely mainly driven by the host genetic background and other demographic factors. IMPORTANCE The genetic association of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) with different clinical conditions remains unclear and needs further investigation. In this study, we characterized 57 complete SARS-CoV-2 genomes from patients in Mexico with distinct disease severity outcomes: mild disease or ambulatory care, severe disease or hospitalized, and deceased. To reduce bias related to risk factors the patients were less than 60 years old and with no diagnosed comorbidities. We did not find evidence for the co-occurrence of mutations associated with specific disease outcomes. Therefore, in the group of patients studied, disease severity was likely mainly driven by the host genetic background and other demographic factors.

Keywords: Mexico; SARS-CoV-2; distinct clinical outcomes; genomic diversity.
 
Back
Top Bottom